Shares of Day One Pharmaceuticals Inc. jumped 21% in premarket trading on Monday after the company shared positive data from an ongoing Phase 2 clinical...
Shares of Day One Pharmaceuticals Inc. DAWN jumped 21% in premarket trading on Monday after the company shared positive data from an ongoing Phase 2 clinical trial for its glioma treatment. Glioma is the most common type of brain tumor in children. The study is assessing tovorafenib; so far, the drug has produced an overall response rate in 64% of participants. Day One said it plans to begin the Food and Drug Administration approval process in the first half of this year.
... Shares of Day One Pharmaceuticals Inc. DAWN jumped 21% in premarket trading on Monday after the company shared positive data from an ongoing Phase 2 clinical trial for its glioma treatment. Glioma is the most common type of brain tumor in children. The study is assessing tovorafenib; so far, the drug has produced an overall response rate in 64% of participants. Day One said it plans to begin the Food and Drug Administration approval process in the first half of this year.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Saturday suggested we may yet be on the way to winterIt seemed a day of atmospheric ambiguity, a day trembling on a meteorological border.
Weiterlesen »
'Every day a holiday' on the National Day CalendarNational Taco Day and National Talk in an Elevator Day aren't quite national holidays, but they do provide excuses for fun (and, in the case of some companies, good marketing opportunities).
Weiterlesen »
This New Luxe Itinerary Takes You to Windsor Castle and Other Historic Estates Throughout BritainLive out your royal fantasy with this one-of-a-kind nine-day voyage.
Weiterlesen »
U.S. FDA approves Alzheimer's drug that appears to slow rate of cognitive declineThe drug, to be sold under the brand Leqembi, belongs to a class of treatments that aims to slow advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain.
Weiterlesen »